


Simultaneous Detection of Single Molecules and Singulated Ensembles of Molecules Enables Immunoassays with Broad Dynamic Range

David M. Rissin, David R. Fournier, Tomasz Piech, Cheuk W. Kan, Todd G. Campbell, Linan Song, Lei Chang, Andrew J. Rivnak, Purvish P. Patel, Gail K. Provuncher, Evan P. Ferrell, Stuart C. Howes,[†] Brian A. Pink, Kaitlin A. Minnehan, David H. Wilson, and David C. Duffy*

Quanterix Corporation, One Kendall Square, Suite B14201, Cambridge, Massachusetts 02139, United States

S Supporting Information

ABSTRACT: We report a method for combining the detection of single molecules (digital) and an ensemble of molecules (analog) that is capable of detecting enzyme label from 10^{-19} M to 10^{-13} M, for use in high sensitivity enzyme-linked immunosorbent assays (ELISA). The approach works by capturing proteins on microscopic beads, labeling the proteins with enzymes using a conventional multistep immunosandwich approach, isolating the beads in an array of 50-femtoliter wells (Single Molecule Array, SiMoA), and detecting bead-associated enzymatic activity using fluorescence imaging. At low concentrations of proteins, when the ratio of enzyme labels to beads is less than ~ 1.2 , beads carry either zero or low numbers of enzymes, and protein concentration is quantified by counting the presence of “on” or “off” beads (digital regime).¹ At higher protein concentrations, each bead typically carries multiple enzyme labels, and the average number of enzyme labels present on each bead is quantified from a measure of the average fluorescence intensity (analog regime). Both the digital and analog concentration ranges are quantified by a common unit, namely, average number of enzyme labels per bead (AEB). By combining digital and analog detection of singulated beads, a linear dynamic range of over 6 orders of magnitude to enzyme label was achieved. Using this approach, an immunoassay for prostate specific antigen (PSA) was developed. The combined digital and analog PSA assay provided linear response over approximately four logs of concentration ([PSA] from 8 fg/mL to 100 pg/mL or 250 aM to 3.3 pM). This approach extends the dynamic range of ELISA from picomolar levels down to subfemtomolar levels in a single measurement.



The enzyme-linked immunosorbent assay (ELISA)^{2–4} has been the cornerstone of sensitive detection of proteins for almost 40 years. ELISA is based on the ensemble detection of many enzyme-labeled proteins in microliter to milliliter volumes and has typically been limited to detecting picomolar (pM) concentrations of proteins. We recently reported a method called digital ELISA¹ based on single molecule arrays (SiMoA)^{5–8} that allows the detection of single enzyme-labeled immunocomplexes by confining them to femtoliter volumes. This approach resulted in a dramatic improvement in immunoassay sensitivity using ELISA reagents, such that subfemtomolar concentrations of proteins could be detected in serum.¹ In this paper, we extend this method to determining wider ranges of concentration by combining single molecule and ensemble detection in one straightforward measurement. This approach has allowed us to measure prostate specific antigen (PSA) in serum over a broad concentration range relevant to a particular clinical application. This paper makes use of several acronyms and symbols; for convenience, Table 1 provides a summary of their definitions.

Many immunodiagnostic applications require both sensitive protein detection and broad analytical ranges (>3 logs in concentration) in order to detect the target protein in the majority of samples. One such example is the detection of PSA in subjects who have undergone radical prostatectomy (RP). We have shown that digital ELISA can measure PSA levels in all men classified as undetectable by conventional immunoassay technology, the lowest being a patient with a PSA level of 14 fg/mL.¹ Measurement of very low levels of PSA may lead to expedited detection of a cancer recurrence event when compared to a conventional ELISA measurement.⁹ PSA levels in some RP patients, however, are known to reach 100 pg/mL shortly after surgery,⁹ so PSA levels can span four logs of concentration in one group of patients. In another example, sensitive measurements of low levels of the serum biomarkers α -fetoprotein and β -human

Received: December 2, 2010

Accepted: January 14, 2011

Published: February 23, 2011

Table 1. Definitions of Some of the Acronyms and Symbols Used in This Paper

acronym	definition
General	
ELISA	enzyme-linked immunosorbent assay
SiMoA	single molecule array
Analytical	
f_{on}	fraction of enzyme-associated (active) beads
AEB	average enzymes per bead
AEB _{digital}	AEB determined by counting active beads
AEB _{analog}	AEB determined from the average intensity of active beads
$\bar{I}_{\text{bead}}$	mean fluorescence intensity of active beads in an array
$\bar{I}_{\text{single}}$	mean fluorescence intensity generated by single enzymes on beads
Biological	
RGP	resorufin- β -D-galactopyranoside, a substrate of β -galactosidase
S β G	conjugate of streptavidin and β -galactosidase
PSA	prostate specific antigen
RP	radical prostatectomy

chorionic gonadotropin¹⁰ could be used to monitor patients for recurrence of testicular cancer after retroperitoneal lymph node dissection. Presurgery levels of α -fetoprotein and β -human chorionic gonadotropin are known to span >3-logs of concentration in these patients,¹⁰ with levels dropping below the detection limit of current assays postsurgery,¹¹ suggesting clinical utility for highly sensitive assays with wide dynamic ranges. In addition, the hormone estradiol is routinely measured to assess the reproductive function in premenopausal women where concentration ranges in serum are greater than five logs.¹² Immunoassays for estradiol have also been used to identify pre- and postmenopausal women at risk for breast cancer, and to monitor for breast cancer recurrence where the absolute concentration of circulating estradiol is much lower.^{13,14} Again, a highly sensitive immunoassay with a broad dynamic range is needed to fulfill the clinical need.

New ultrasensitive immunoassays^{1,15–17} are needed because the concentration of many biomarkers extend below the working range of currently used clinical assays, and it is believed that most serum proteins are, in fact, currently undetectable.¹⁸ Ultrasensitive techniques are often capable of measuring low concentrations of a protein in a sample but are not able to measure the high end of the concentration range without sample dilution and retesting. It is often not possible, therefore, to measure the broad range of concentrations encountered in clinical samples in a single assay using ultrasensitive methods. While diluting sample circumvents the insufficient working range of ultrasensitive assays, in a clinical setting it is preferable to measure all samples in a single pass. By successfully quantitating the concentration of protein in the vast majority of samples in a single test, assay throughput and result turnaround time to the clinician will be improved.

Here, we present a technique for extending digital measurement of enzyme labels using SiMoA into the analog regime, enabling linear detection of enzyme label across six logs of concentration. With the goal of extending the working range of immunoassays, we applied this technique to digital ELISA for

PSA. The working range of the combined digital and analog PSA assay was >4 logs, detecting PSA in serum from 0.008 pg/mL to 100 pg/mL.

EXPERIMENTAL SECTION

Materials and Methods. The materials and procedures used for forming enzyme-labeled complexes on beads in the enzyme label and PSA assays, preparing femtoliter-volume well arrays, and loading beads into these arrays have been described elsewhere¹ and are provided in the Supporting Information.

Imaging and Analysis of Beads and Enzyme-Associated Beads in Femtoliter-Volume Well Arrays. A microscope-based imaging system, containing a metal halide light source, filter cubes, objectives, and a CCD camera was used to image enzyme-associated beads in well arrays formed at the end of fiber bundles.^{19,8} Strips of eight fiber bundles arrays were assembled by gluing the bundles into custom-made glass holders. A strip was clamped on the microscope stage using a custom fixture. A droplet of substrate to β -galactosidase (RGP) was placed on a silicone gasket material and placed in contact with the well arrays. A precision mechanical platform moved the silicone gasket into contact with the end of the fiber bundle, creating an array of isolated femtoliter-volume reaction vessels containing RGP. Fluorescence images were acquired (577 nm excitation; 620 nm emission) with an exposure time of 1011 ms to detect enzymatic activity in the wells. Five fluorescence images (at 30-s intervals) were taken for each femtoliter-volume well array. After the fluorescence images were acquired, the arrays were illuminated with white light and imaged on the CCD camera. The white light and fluorescence images were analyzed using customized software to determine the presence of beads and enzymatic activity, respectively. First, the white light image was analyzed to determine which wells contained a bead. Due to scattering of light by the beads, those wells that contained a bead appeared brighter in the image than wells without beads. Second, regardless of signal levels, all fluorescence images were analyzed the same way. The fluorescence intensities of each well in each array of all five fluorescent images were first determined. The digital signal (“on” or “off”) of each well containing a bead was assigned by determining whether or not the fluorescence intensity increased in each successive image, and by at least 20% over four images. Wells containing a bead that met these criteria were assigned as “on” or active; those that did not meet these criteria were assigned as “off”. The digital signal, i.e., the fraction of “on” beads for each array (f_{on}), was then determined. The analog signal of each “on” bead was determined from the difference in its fluorescence intensity between the second and first fluorescence images ($I_{\text{bead},F2} - I_{\text{bead},F1}$). The analog signal of the array ($\bar{I}_{\text{bead}}$) was the average of $I_{\text{bead},F2} - I_{\text{bead},F1}$ over all “on” beads.

RESULTS AND DISCUSSION

Singulated Bead ELISA Format. In the first step of the singulated bead ELISA, microscopic beads coated in antibodies capture the target protein from serum, plasma, or another complex sample, followed by labeling the bound proteins with enzyme reporter molecules. Enzyme labeling of the proteins is achieved by the formation of an immunocomplex in two steps, using a biotinylated detection antibody and a streptavidin–enzyme conjugate. The capture beads are then loaded into an




Figure 1. The signal output of SiMoA at different regimes of enzyme/bead ratios. (Left) At AEB = 0.1, active beads are statistically associated predominantly with single enzymes, and the SiMoA readout is essentially “single molecule”. (Center) At AEB = 0.6, a significant number of active beads have multiple enzymes bound. The images are still analyzed by counting “on” wells so quantitation is digital. Multiple enzymes per bead are accounted for in data analysis using the Poisson distribution. (Right) At AEB = 3, almost every bead has at least one enzyme associated with it. In this case, the average number of enzymes per bead is quantitated by measurement of the average fluorescence intensity of the active beads and from knowledge of the average fluorescence intensity generated by a single enzyme.

array of femtoliter-sized microwells, and the loaded array is sealed against a silicone gasket in the presence of a droplet of fluorogenic enzyme substrate, isolating each bead in a femtoliter reaction chamber. Beads associated with bound enzyme label or labels generate a locally high concentration of fluorescent product in the 50-fL reaction chambers. By using standard fluorescence imaging, it is possible to image tens of thousands of enzyme-associated beads simultaneously (Figure S-1, Supporting Information). Depending on the fraction of beads that have one or more enzymes associated with them, the assay signal is determined by either digital or analog analysis methods to quantify the number of enzyme labels per bead detected (Figure 1). Figure S-1 contains examples of fluorescence images that are represented schematically in Figure 1. At low ratios of

enzyme labels to beads, where there are a significant number of beads that are associated with no enzyme (“off” beads), the number of active, enzyme-associated (or “on”) beads relative to the total number of beads detected are used to determine an average enzyme per bead (AEB) via Poisson statistics. As concentration is determined from counting “on” beads and is independent of the fluorescence intensity generated in the well, we refer to this approach as ‘digital’. At higher ratios of enzyme labels to beads, when most beads have one or more enzyme labels bound, the counting approach no longer works. In this situation, AEB (and, therefore, protein concentration) is determined from the average fluorescence intensity of wells containing a bead in the array ($\bar{I}_{\text{bead}}$); we refer to this approach as ‘analog’. Currently, the analog approach is used to analyze images with >70% active




Figure 2. (A) Plot of fraction of active beads against the effective concentration, given by AEB, determined from digital counting using the Poisson distribution (eq 2). As concentration increases, the slope of % active gets shallower and signal imprecision leads to greater imprecision in concentration determined. (B) Plot of analog intensity ($I_{\text{bead}}/I_{\text{single}}$) as a function of effective concentration, AEB (eq 3). At low concentrations, variation in intensity measurements makes it impractical to detect small increases in multiple enzymes, and CVs of extrapolated AEB are high. (C) Plots of imprecision in AEB (% CV) as a function of f_{on} from digital (blue line) and analog (red line) analyses assuming a fixed signal CV of 7.1% for both methods. This signal CV was determined empirically by fitting AEB imprecision data from the PSA digital ELISA collected over six days.

beads. To convert $\bar{I}_{\text{bead}}$ to AEB in the analog regime, we make use of the digital measurements. First, images with <10% active beads are used to determine the average analog intensity of a single enzyme molecule ($\bar{I}_{\text{single}}$). The ratio of $\bar{I}_{\text{bead}}$ to $\bar{I}_{\text{single}}$ over all beads provides the analog AEB. The digital and analog analytical regimes are described in detail below.

Digital Determination of Protein Concentration. To determine protein concentration in samples, known standards are spiked into bovine serum or plasma, and SiMoA is used to generate a calibration curve of AEB versus concentration. SiMoA is then used to determine AEB for unknown samples that are compared to the calibration curve to determine concentration. At low ratios of enzymes to beads, when there are a statistically significant number of beads with no enzymes, by measuring the fraction of active beads in a population it is possible to determine the bulk analyte concentration because the binding probability of a population of analyte molecules to a population of beads is defined by the Poisson distribution. At very low ratios of labeled analyte to beads (less than about 0.1 enzyme labels per bead), most beads have either zero or one labeled analyte molecule and the percentage of active beads increases approximately linearly with increasing analyte concentration. As the fraction of active beads becomes larger (>0.1), Poisson statistics show that there are a significant number of beads with multiple enzymes. If the fraction of active beads is plotted against concentration, linearity is lost at high target concentrations because active beads that have multiple enzyme molecules bound contribute the same 'digital' signal as an active bead that has one enzyme bound

(Figure S-2, Supporting Information). To quantitate the number of detected enzymes and to maintain linearity in the subpopulations of beads with multiple enzymes, we use Poisson statistics to convert the fraction of active beads to AEB.

The Poisson distribution (eq 1) describes the likelihood of a number of events occurring if the average number of events is known. If the expected average number of occurrences is μ , then the probability that there are exactly ν occurrences (ν being a non-negative integer, $\nu = 0, 1, 2, 3$, etc.) is equal to:

$$P_{\mu}(\nu) = e^{-\mu} \left(\frac{\mu^{\nu}}{\nu!} \right) \quad (1)$$

In digital ELISA, μ is equal to the ratio of bound labeled proteins to the number of beads, and ν is the number of enzyme-labeled proteins carried by each subpopulation of beads (i.e., 0, 1, 2, 3, etc.). The aim of the SiMoA experiment is to determine μ , which by definition is equal to AEB, and use it as the quantitative parameter to determine protein concentration. In the digital mode of analysis where beads are identified as being either "on" or "off", then $\nu = 1, 2, 3$ are indistinguishable and characterized as "on" beads. A bead associated with one enzyme is indistinguishable from a bead associated with two enzymes due to the static heterogeneity of enzyme activity, where populations of individual enzyme molecules have been shown to have up to a 7-fold distribution in enzymatic activity.^{6,20–22} Because of this broad distribution, only occurrences of $\nu = 0$ can be determined definitively as the fraction of "off" beads ($P_{\mu}(0)$). Using eq 1 to determine $P_{\mu}(0)$, and the fact that the fraction of "off" beads is

equal to one minus the fraction of “on” beads, it is possible to determine AEB_{digital} (the digitally determined AEB) from f_{on} (the fraction of “on” beads or % active) (eq 2):

$$\mu = AEB_{\text{digital}} = -\ln[1 - f_{\text{on}}] \quad (2)$$

Figure S-2 demonstrates the effectiveness of the Poisson distribution analysis in the digital range of a calibration curve using an assay for streptavidin- β -galactosidase ($S\beta G$) that creates beads with well-defined enzyme/bead ratios.¹ In brief, beads were functionalized with a biotinylated capture molecule, and these beads were used to capture various concentrations of the $S\beta G$ enzyme conjugate that we use as a label in digital ELISA. The beads were loaded into the femtoliter arrays and, after sealing a solution of RGP into the wells of the array, fluorescence was generated from bound enzymes accumulated in the reaction chambers for 2.5 min, with fluorescent images acquired every 30 s. A white light image of the array was acquired at the end of the experiment. These images were analyzed to identify wells that contained beads (from the white light image) and determine which of those beads had associated bound enzyme molecules (from time-lapsed fluorescent images), as described previously.¹ Figure S-2 shows that AEB_{digital} determined from eq 2 maintained a linear response up to 50% active, despite nonlinear variation in f_{on} .

Analog Determination of Protein Concentration. While quantification of concentration using counting and Poisson statistics works well below 70% active beads, as the fraction of active beads exceeds about 70%, the change in AEB with concentration is reduced, leading to greater imprecision of concentration determination (Figure 2A). The counting approach ultimately breaks down when every bead has at least one bound enzyme.

We extend the dynamic range of the SiMoA assay beyond the digital regime by measuring the average fluorescence intensity of wells that contain beads to determine the number of enzymes associated with each bead detected. For this analysis, AEB can be determined from the average fluorescence intensity value of the active beads ($\bar{I}_{\text{bead}}$) and the average fluorescence intensity generated by a single enzyme ($\bar{I}_{\text{single}}$). The AEB of an array in the analog range (AEB_{analog}) is defined by eq 3:

$$AEB_{\text{analog}} = \frac{f_{\text{on}} \times \bar{I}_{\text{bead}}}{\bar{I}_{\text{single}}} \quad (3)$$

To determine $\bar{I}_{\text{single}}$, we equate the digital (eq 2) and analog (eq 3) AEB terms at fractions of active beads where single enzymes dominate and substrate depletion is negligible (eq 4); we chose arrays with fractions of “on” beads <0.1 that meet these criteria:

$$\bar{I}_{\text{single}} = \frac{f_{\text{on}} \times \bar{I}_{\text{bead}}}{-\ln[1 - f_{\text{on}}]} \text{ in arrays where } f_{\text{on}} < 0.1 \quad (4)$$

AEB can then plotted for both the digital (AEB_{digital} (eq 2)) and analog (AEB_{analog} (eq 3)) ranges, and the two curves are seamlessly meshed into one calibration curve.

In order to combine digital and analog data, each experiment ideally requires arrays where the fraction of active beads is less than 10% (eq 4). This requirement is achieved using the calibration data points that cover this range, or specific control samples known to have this digital signal. With two or three concentrations in a calibration curve with $f_{\text{on}} < 0.1$, the kinetic activities of




Figure 3. Broad dynamic range to enzyme label was achieved by combining digital and analog measurements in SiMoA. (A) Plot of AEB as a function of enzyme concentration. The error bars are standard deviations over three replicates. (B) % active and AEB values as a function of enzyme concentration. AEB was determined using eq 2 for % active <70%. AEB was determined using eq 3 for % active >70%. The threshold between analog and digital in this experiment was between 10 fM and 31.6 fM.

thousands of individual enzyme molecules are averaged to determine $\bar{I}_{\text{single}}$. Because the activities of thousands of molecules are averaged, the intrinsic variation associated with single enzyme molecule velocities described above does not add significant uncertainty in the $\bar{I}_{\text{single}}$ values. The uncertainty in the mean single enzyme intensity ($\bar{I}_{\text{single}}$) as a function of N measurements²³ is given by $\sigma_{\bar{I}_{\text{single}}}/N^{1/2}$, where $\sigma_{\bar{I}_{\text{single}}}$ is the width parameter of the normally distributed single enzyme molecule intensities. The width parameter in single enzyme molecule velocities is 20–30% of the average velocity,⁶ so the uncertainty added to the mean value $\bar{I}_{\text{single}}$ from enzyme variation is less than 1% when averaging over 1000 single molecule measurements.

There is a significant range of fraction of active beads (10–99.98%) where theoretically digital counting and analog intensities could both be used to determine AEB. Below 10%, the contribution of beads associated with multiple enzymes is small and $\bar{I}_{\text{bead}}$ does not vary above measurement noise with % active, so the analog approach does not work. As f_{on} approaches 100%, counting cannot be used to digitally determine AEB. Between these two extremes, imprecision considerations (manifested by




Figure 4. The combined digital and analog SiMoA PSA assay with a 4-log working range and calculated LOD of 0.008 pg/mL. AEB is plotted as a function of PSA concentration in linear–linear space (left) and log–log space (right). Error bars are shown for all data points based on quadruplicate measurements.

the coefficient of variation (% CV) of AEB) determine the threshold of the fraction of active beads below which AEB_{digital} (eq 2) is used and above which AEB_{analog} (eq 3) is used. The choice of this threshold is illustrated by plotting the imprecision in AEB arising from the variation in digital and analog signals from 10 to 100% active beads (Figure 2C). Close to 10% active beads, changes in $\bar{I}_{\text{bead}}$ above single molecule values are small as AEB increases, leading to high imprecision in AEB. As the % active goes above 70% and the Poisson distribution curves deviates from linearity, the change in AEB_{digital} with % active decreases, leading to greater imprecision in the AEB_{digital} determined. The balance of imprecision profiles in this overlap zone (Figure 2C) led us to choose the ‘digital-to-analog’ threshold as 70% active (around $AEB = 1.2$).

Combined Digital and Analog Enzyme Label Detection. The $S\beta G$ binding assay described in the Supporting Information and elsewhere¹ was used to demonstrate the dynamic range to enzyme label that can be achieved by combining digital and analog determination of AEB. Figure 3 shows AEB determined from SiMoA images of populations of biotin-presenting beads that had been incubated with concentrations of $S\beta G$ ranging from zeptomolar to picomolar. For images with % active beads <70%, AEB_{digital} was determined using eq 2. All the arrays with <10% active beads were used to determine $\bar{I}_{\text{single}}$; a total of 7566 beads; $\bar{I}_{\text{single}}$ was equal to 298 au. The average fluorescence intensities of beads in images with over 70% active were determined, and AEB_{analog} values were calculated using eq 3. Because the 0 M $S\beta G$ concentration yielded no active beads, the lower limit of detection in this experiment could not be calculated using the background plus 3 SD method. Using our previously established LOD of 220 zM,¹ and the highest concentration detected in the linear range of this curve, 316 fM, we determined a 6.2-log linear dynamic range for detecting enzyme label. The linear digital dynamic range was 4.7 logs; the analog linear dynamic range was 1.5 logs.

The dynamic range of the analog SiMoA measurement is affected by substrate depletion, timing of sealing and imaging by the system, and dynamic range of the camera. These issues are discussed in detail in the Supporting Information.

Combined Digital and Analog ELISA for Measuring PSA in Serum. We next sought to implement the combined digital and analog approach to develop a SiMoA ELISA for PSA with a wide dynamic range. Clinically, PSA is used to screen for prostate cancer and to monitor for biochemical recurrence of the disease in patients who have undergone surgery to remove the cancer. The PSA levels in the serum of patients who have undergone radical prostatectomy (RP) are known to range from 0.014 pg/mL¹ to over 100 pg/mL.⁹

Table 2. Summary of AEB and [PSA] Determined for 17 Serum Samples from Post-RP Patients^a

sample ID	mean AEB	std dev AEB	AEB CV, %	[PSA] (pg/mL)	std dev [PSA]	[PSA] CV, %
S640	8.8	1.2	13	41.0	7.5	18
S641	0.87	0.08	10	4.1	0.4	11
S643	0.23	0.002	1	1.1	0.01	1
S644	15.2	1.0	6	136	13	10
S645	1.5	0.06	4	6.1	0.2	4
S647	11.0	0.1	1	80.4	1.9	2
S648	7.4	0.3	3	32.3	1.6	5
S649	1.5	0.2	11	6.1	0.6	10
S650	0.22	0.008	4	1.2	0.03	2
S651	0.50	0.02	5	2.3	0.1	4
S615	12.6	1.0	8	70.7	8.6	12
S653	1.3	0.2	18	5.0	0.8	16
S616	0.44	0.05	12	1.7	0.2	13
S618	13.6	0.7	5	79.2	6.2	8
S624	14.8	0.5	3	88.9	4.1	5
S627	0.098	0.003	3	0.39	0.01	3
S628	0.92	0.04	5	3.7	0.15	4

^aStandard deviations and CVs were determined over triplicate tests. Sample S644 had an AEB value beyond the range of the calibration curve, but its concentration was determined by extrapolation.

To successfully measure the PSA levels in the majority of patients in a single test requires an assay with 4 logs of dynamic range. A SiMoA ELISA for PSA was developed and run as described in the Supporting Information. Figure 4 shows that by combining digital and analog analyses, the working range of the SiMoA PSA assay was from 0.008 pg/mL to 100 pg/mL, enabling precise quantification of PSA levels in the vast majority of RP patient samples in one pass.

We used this assay to measure the concentration of PSA in the sera of 17 prostate cancer patients collected at 2 to 46 weeks (mean = 13.8 weeks) after radical prostatectomy surgery. These samples were collected closer to surgery than our previous study¹ that, in order to push the lower limits of detection of digital ELISA, tested samples collected an average of 8 years postsurgery of patients whose cancer did not recur. Here, in order to evaluate the dynamic range of the assay across the intended clinical range, samples collected closer to surgery were tested to capture patients with higher PSA whose cancer could recur. PSA was,

however, undetectable in all of these samples using a leading PSA diagnostic test (Siemens). Serum samples were diluted 1:4 in buffer, and AEB was measured using SiMoA. The concentration of PSA for each sample was determined by reading the AEB off a simultaneously acquired calibration curve similar to Figure 4. Table 2 summarizes the AEB and PSA concentrations determined from these samples, along with the imprecision for signal and concentration given by % CV. PSA was quantified in all of the samples in one experiment. The average PSA concentration in these samples was 33 pg/mL, with a high of 136 pg/mL and a low of 0.4 pg/mL. When combined with our previous measurements of PSA in RP patients,¹ SiMoA has detected concentrations of PSA in clinical samples from 0.46 fM (0.014 pg/mL) to 4.5 pM (136 pg/mL), demonstrating the importance of an assay with good dynamic range. The PSA levels in Table 2 are significantly higher than from the set of samples that we previously tested¹ that were collected from known, nonrecurring patients, typically several years postsurgery. Presumably, the levels detected in this study are more indicative of patients soon after surgery and will contain individuals whose cancer might recur.

CONCLUSIONS

The transition from extremely sensitive digital detection of single molecules to analog detection of ensembles of molecules was achieved with two enhancements to the SiMoA approach. First, a Poisson distribution analysis was applied to account for both single and multiple enzymes per bead from 0 to 70% active to determine the digital AEB value. Second, the average analog intensities of beads in images at over 70% active beads were converted to AEB using the average intensity for a single enzyme. These two analytical approaches permit linear measurement of AEB from 0.00005 to ~15. For PSA, combining the analog and digital analyses extended the working range to 4.1 logs of concentration from the original digital working range of 2.5 logs.

We are currently working on extending the working range of SiMoA an additional 1–2 orders of magnitude by improving the speed of the imaging system and minimizing the impact of substrate depletion. By further expanding the range of our assays, we hope to successfully measure all samples in a single assay cycle to improve assay throughput and reduce the cost of immunoassays.

ASSOCIATED CONTENT

S Supporting Information. Additional information as noted in the text. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: dduffy@quanterix.com.

Present Addresses

[†]Biophysics Graduate Group, 299 Life Science Addition, MC 3200, University of California, Berkeley, CA 94720-3200.

ACKNOWLEDGMENT

The authors thank Dr. David Hanlon for helpful discussions. The project described was supported in part by Award Number R43CA133987 from the National Cancer Institute.

REFERENCES

- (1) Rissin, D. M.; Kan, C. W.; Campbell, T. G.; Howes, S. C.; Fournier, D. R.; Song, L.; Piech, T.; Patel, P. P.; Chang, L.; Rivnak, A. J.; Ferrell, E. P.; Randall, J. D.; Provuncher, G. K.; Walt, D. R.; Duffy, D. C. *Nat. Biotechnol.* **2010**, *28*, S95–S99.
- (2) Gosling, J. P. *Clin. Chem.* **1990**, *36*, 1408–1427.
- (3) Wild, D. *The Immunoassay Handbook*, 3rd ed.; Elsevier: New York, 2005.
- (4) Zhang, H. Q.; Zhao, Q.; Li, X. F.; Le, X. C. *Analyst* **2007**, *132*, 724–737.
- (5) Gorris, H. H.; Rissin, D. M.; Walt, D. R. *Proc. Nat. Acad. Sci. U.S.A.* **2007**, *104*, 17680–17685.
- (6) Rissin, D. M.; Gorris, H. H.; Walt, D. R. *J. Am. Chem. Soc.* **2008**, *130*, 5349–5353.
- (7) Rissin, D. M.; Walt, D. R. *J. Am. Chem. Soc.* **2006**, *128*, 6286–6287.
- (8) Rissin, D. M.; Walt, D. R. *Nano Lett.* **2006**, *6*, 520–523.
- (9) Eisenberg, M. L.; Davies, B. J.; Cooperberg, M. R.; Cowan, J. E.; Carroll, P. R. *Prognostic Implications of an Undetectable Ultrasensitive Prostate-Specific Antigen Level after Radical Prostatectomy*; Elsevier: Kidlington, ROYAUME-UNI, 2010; Vol. 57.
- (10) Spiess, P. E.; Brown, G. A.; Liu, P.; Tannir, N. M.; Tu, S. M.; Evans, J. G.; Czerniak, B.; Kamat, A. M.; Pisters, L. L. *Cancer* **2006**, *107*, 1483–1490.
- (11) Bartlett, N.; Freiha, F.; Torti, F. *Hematol. Oncol. Clin. North Am.* **1991**, *5*, 1245.
- (12) Burger, H. G.; Dudley, E. C.; Hopper, J. L.; Groome, N.; Guthrie, J. R.; Green, A.; Dennerstein, L. *J. Clin. Endocrinol. Metab.* **1999**, *84*, 4025–4030.
- (13) Group, E. H. a. B. C. C. *Cancer Epidemiol. Biomarkers Prev.* **2003**, *12*, 1457–1461.
- (14) Eliassen, A. H.; Missmer, S. A.; Tworoger, S. S.; Spiegelman, D.; Barbieri, R. L.; Dowsett, M.; Hankinson, S. E. *J. Natl. Cancer Inst.* **2006**, *98*, 1406–1415.
- (15) Armani, A. M.; Kulkarni, R. P.; Fraser, S. E.; Flagan, R. C.; Vahala, K. J. *Science* **2007**, *317*, 783–787.
- (16) Bao, Y. P.; Wei, T. F.; Lefebvre, P. A.; He, H. A. L.; Kunkel, G. T.; Muller, U. R. *Anal. Chem.* **2006**, *78*, 2055–2059.
- (17) Todd, J.; Freese, B.; Lu, A.; Held, D.; Morey, J.; Livingston, R.; Goix, P. *Clin. Chem.* **2007**, *53*, 1990–1995.
- (18) Anderson, N. L.; Polanski, M.; Pieper, R.; Gatlin, T.; Tirumalai, R. S.; Conrads, T. P.; Veenstra, T. D.; Adkins, J. N.; Pounds, J. G.; Fagan, R.; Lobley, A. *Mol. Cell. Proteomics* **2004**, *3*, 311–326.
- (19) Pantano, P.; Walt, D. R. *Chem. Mater.* **1996**, *8*, 2832–2835.
- (20) Craig, D. B.; Arriaga, E. A.; Wong, J. C. Y.; Lu, H.; Dovichi, N. J. *J. Am. Chem. Soc.* **1996**, *118*, 5245–5253.
- (21) Craig, D. B.; Dovichi, N. J. *Can. J. Chem.* **1998**, *76*, 4.
- (22) Xue, Q.; Yeung, E. S. *Nature* **1995**, *373*, 681–683.
- (23) Taylor, J. R. In *An Introduction to Error Analysis: The Study of Uncertainties in Physical Measurements*; University Science Books: Sausalito, CA, 1997.

Simultaneous Detection of Single Molecules and Ensembles of Molecules Enables Immunoassays with Broad Dynamic Range

David M. Rissin, David R. Fournier, Tomasz Piech, Cheuk W. Kan, Todd G. Campbell, Linan Song, Lei Chang, Andrew J. Rivnak, Purvish P. Patel, Gail K. Provuncher, Evan P. Ferrell, Stuart C. Howes,[†] Brian A. Pink, Kaitlin A. Minnehan, David H. Wilson & David C. Duffy^{*}

Quanterix Corporation, One Kendall Square, Suite B14201, Cambridge, MA 02139, USA.

Supporting Information Table of Contents

Supporting Experimental Section. Page S-2.

Supporting Figure S-1. SiMoA fluorescence images at AEB levels of approximately 0.1, 0.6, and 3.0. **Page S-5.**

Supporting Figure S-2. Conversion of fraction of active beads to AEB_{digital} using Poisson statistics. **Page S-6.**

Supporting Text. Factors affecting the dynamic range of SiMoA analog measurements. **Page S-7.**

Supporting Figure S-3. Michaelis-Menten curve of streptavidin- β -galactosidase and RGP. **Page S-9.**

Supporting Figure S-4. Theoretical curves of production of fluorescent product as a function of the number of enzymes per bead based on Michaelis-Menten kinetics of streptavidin- β -galactosidase and RGP. **Page S-9.**

Supporting Table S-1. Data showing the effect of substrate depletion on substrate turnover over time, as a function of the number of enzyme molecules confined to a well. **Page S-10.**

Supporting Experimental Section

Materials. Optical fiber bundles were purchased from Schott North America. Non-reinforced gloss silicone sheeting was obtained from Specialty Manufacturing. Hydrochloric acid, anhydrous ethanol, molecular biology-grade Tween-20, and β -galactosidase were all from Sigma-Aldrich. Carboxyl-terminated magnetic beads (2.7- μ m diameter) were purchased from Varian. Monoclonal capture antibody to PSA, monoclonal detection antibody to PSA, and purified PSA were purchased from BiosPacific. Streptavidin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), and SuperBlock T-20 Blocking Buffer were purchased from Thermo Scientific. The Chromalink™ biotinylation reagent was purchased from Solulink, Inc. Purified DNA was purchased from Integrated DNA Technologies. Resorufin- β -D-galactopyranoside (RGP) was purchased from Invitrogen. The fiber polisher and polishing consumables were purchased from Allied High Tech Products.

Preparation and characterization of biotinylated detection antibodies and enzyme

conjugates. Detection antibodies were biotinylated using the Chromalink™ biotinylation reagent. This reagent contains a succinimidyl ester group that attaches biotin groups to the antibody via lysine residues, and a bis aryl hydrazone chromophore that allows quantification of the number of biotin molecules per antibody¹. The average number of biotin groups on the anti-PSA antibody ranged from 7.5 to 9.5. Streptavidin- β -galactosidase (S β G) was conjugated in the laboratory using standard protocols². HPLC characterization of the conjugate indicated that >80% of the conjugate molecules contained one β -galactosidase molecule, with an average of 1.2 enzymes/conjugate. Comparison to molecular weight standards indicated that the average number of streptavidin molecules conjugated to each enzyme molecule was 2.7. As each detection antibody contains multiple biotin groups, it is possible that a single protein molecule

bound to a single detection antibody could be bound to multiple enzyme conjugates. Analysis of the fluorescence intensity generated by enzyme-associated beads in the single molecule regime ($\text{AEB} < 0.1$) suggests, however, that multiple enzyme conjugates did not bind to single detection antibody molecules: these fluorescent intensities were consistent with the kinetics of single molecules of β -galactosidase as previously published³.

Preparation of magnetic beads presenting biotin-labeled DNA and capture of enzyme

conjugate. Beads functionalized with DNA capture probe (5'-NH₂/C12-GTT GTC AAG ATG CTA CCG TTC AGA G-3') were prepared according to the manufacturer's instructions. These beads were incubated with 1 μM of biotinylated complementary DNA (5'-biotin-C TCT GAA CGG TAG CAT CTT GAC AAC-3') overnight (16 h) in TE buffer containing 0.5 M NaCl and 0.01% Tween-20. After incubation, the beads were washed three times in PBS buffer containing 0.1% Tween-20. A bead concentration of 200,000 beads per 100 μL of S β G target solution was used. Beads were incubated in target solutions diluted in SuperBlock containing 0.05% Tween-20 for 4 h. 100 μL of the various target solutions were aliquotted into a microtiter plate. The beads were separated with a microtiter plate magnet and washed six times with 5 $\times$ PBS buffer containing 0.1% Tween-20. For SiMoA detection, the beads were resuspended in 10 μL of PBS containing 0.1% Tween-20, and the aliquots were loaded onto a femtoliter-volume well array.


Capture of PSA on magnetic beads and formation of enzyme-labeled immunocomplexes.

Beads functionalized with a monoclonal antibody to PSA were prepared according to the manufacturer's instructions. Test solutions (100 μL) were incubated with suspensions of 500,000 magnetic beads for 2 h at 23 $^{\circ}\text{C}$. The beads were then separated and washed three times in 5 $\times$ PBS and 0.1% Tween-20. The beads were resuspended and incubated with solutions

containing detection antibody (~1 nM) for 60 min at 23 °C. The beads were then separated and washed three times in 5× PBS and 0.1% Tween-20. The beads were incubated with solutions containing SβG (15 pM) for 30 min at 23 °C, separated and washed seven times in 5× PBS and 0.1% Tween-20. The beads were then resuspended in 25 μL of PBS, and 10 μL of the bead solution was loaded onto a femtoliter-volume well array.

Preparation of femtoliter-volume well arrays. Optical fiber bundles approximately 27 mm long were sequentially polished on a polishing machine using 30-, 9-, 3-, and 1-μm-sized diamond lapping films. The polished fiber bundles were chemically etched in a 0.025 M HCl solution for 130 s, and then immediately submerged into water to quench the reaction. The etched fibers were sonicated for 5 s in water and dried under vacuum. The differential etch rate of the core and cladding glass of the fiber bundle arrays caused 4.5-μm-diameter wells to be formed in the core fibers with well depths of 3.25 ± 0.5 μm. These dimensions were optimal for retaining single beads in wells while maintaining good seals.

Loading of beads into femtoliter-volume well arrays. A short length of PVC tubing was placed on the etched end of a fiber bundle to create a reservoir to hold the bead solution. 10 μL of the concentrated bead solution were pipetted into this reservoir. The fiber bundle was then centrifuged at 1300 g for 10 min to allow the beads to settle into the etched wells. The PVC tubing was removed after centrifugation. The fiber bundle was dipped in PBS solution to wash off excess bead solution, and the surface was swabbed with deionized water. Bead concentrations of 200,000 per 10 μL were loaded, typically resulted in 40–60% of wells in a 50,000-well array being occupied by a single bead.




Supporting Figure S-1. Fluorescence images generated using SiMoA of singulated beads at approximately (A) AEB ~ 0.1 , where the majority of beads were associated with 0 or 1 enzyme molecules, (B) AEB ~ 0.6 , where a significant number of beads were associated with multiple enzyme molecules, and (C) AEB ~ 3.0 , where all beads were associated with at least 1 enzyme molecule. The images shown are of the analog, fluorescence signal generated by the experiment, i.e., $(I_{\text{bead},F2} - I_{\text{bead},F1})$ (see main text).

A

[S β G] (fM)	f_{on} (% active beads)	$\mu = AEB_{digital}$
0.6	5.07	0.0521
0.8	7.10	0.0736
1	8.89	0.0931
2	16.29	0.1778
4	31.33	0.3759
6	43.84	0.5769
8	53.42	0.7639

B



Supporting Figure S-2. (A) Conversion of % active beads to $AEB_{digital}$ using Poisson statistics. The center column is the fraction of active beads determined by digital counting as a function of enzyme concentration. The right column is the average enzyme per bead (AEB) determined from % active beads using eq. 2. This conversion accounts statistically for beads associated with multiple enzyme molecules using a digital counting method. (B) Plots of % active beads (blue diamonds) and $AEB_{digital}$ (red squares) as a function of enzyme concentration. The % active beads deviates from linearity with increasing concentration as expected from the Poisson distribution. In this experiment, $AEB_{digital}$ was linear with concentration up to about 50% active beads. Error bars were determined from the standard deviation over three measurements.


Supporting Text

Factors affecting the dynamic range of SiMoA analog measurements. While the digital and analog determination of AEB can be combined to extend the dynamic range of SiMoA, three factors put an upper bound on analog measurements: substrate depletion; timing of sealing and imaging by the system; and dynamic range of the camera.


While substrate depletion is not an issue when dealing with single enzymes bound to single beads that are confined to a 50-fL reaction chamber, it poses a potential problem as larger numbers of enzyme molecules are confined to an individual reaction chamber. The production of fluorescent product molecules within a well containing n enzymes can be modeled by consideration of the (finite) number of substrate molecules in the reaction chamber, and the Michaelis constant (K_M) of the enzyme/substrate pair. Under typical experimental conditions, there are approximately 2.1 million substrate molecules available for turnover in the confined beaded reaction chamber, and the average enzyme turnover rate of RGP by β -galactosidase is 186 s^{-1} at $100\text{ }\mu\text{M}$ substrate concentration (**Figure S-3**). We have shown that the K_M of streptavidin- β -galactosidase with RGP is $217\text{ }\mu\text{M}$ (**Figure S-3**); similar values have been determined previously for unconjugated β -galactosidase⁴. As the substrate concentration is decreased due to depletion, turnover changes dramatically with a change in substrate concentration near K_M , and using $100\text{ }\mu\text{M}$ RGP in our system makes us susceptible to this effect. As enzyme converts substrate into product, the effective RGP concentration drops over time, and in turn, the turnover of substrate drops (**Table S-1**). If there is only one enzyme molecule bound to a bead, only 1.34% of substrate is converted into product during our 150 s SiMoA measurement, and the enzyme maintains 99% of its activity. On the other hand, if there are, on average, 50 enzyme molecules bound per bead, 43% of the overall activity per enzyme is lost by

the end of the experiment due to substrate depletion. The effect of depletion on reaction rate could be mitigated by using a much higher substrate concentration. We are limited, however, to 100 μ M RGP by its solubility in our buffers. **Figure S-4** (green line) shows a theoretical curve of the amount of RGP converted into resorufin over the course of a SiMoA measurement from a 100 μ M RGP solution as a function of the number of enzyme molecules in a sealed well containing a bead, taking substrate depletion into account. Assuming a camera without limited sensitivity and imaging starting immediately after sealing, the assay should remain approximately linear to over AEB = 50.

While substrate depletion will ultimately limit the dynamic range of the SiMoA assay, the time between sealing the arrays and acquiring the first image, along with the dynamic range of the CCD camera, currently limit dynamic range. The current SiMoA system takes approximately 45 s to acquire the first fluorescence image because of auto-focusing steps. During this time there is significant consumption of substrate and this factor limits the number of resorufin molecules that are generated after the first fluorescence image is acquired (blue line of **Figure S-4**) and, therefore, the dynamic range in $\bar{I}_{\text{bead}}$ that can be achieved. If the imaging could be performed more quickly, then dynamic range could be increased (green line of **Figure S-4**). The dynamic range of the camera, however, places its own limit on the range of concentrations of enzyme label that can be measured. At high target concentrations corresponding to high AEB, the rate of RGP conversion to fluorescent product is so rapid that the active wells saturate the detector when the first image is acquired. Because the 12-bit CCD camera currently used in the system becomes saturated above about 1.2 million resorufin molecules per well, subsequent images will also be saturated, and increases in fluorescence cannot be measured. The use of wider dynamic range cameras (e.g., 14-bit) would remove this limitation.



Supporting Figure S-3. Michaelis-Menten curve of RGP turnover by streptavidin- β -galactosidase. K_M and V_{max} were calculated using curve fitting software (GraphPad) to be 217 μM and 591 s^{-1} , respectively.



Supporting Figure S-4. Plot of the number of resorufin molecules produced during a 150 s experiment as a function of the number of enzymes on a bead. The theoretical limit of our system (green curve) is modeled where image acquisition begins at $t=0$, immediately when the seal is made, and before any RGP is converted into resorufin. The current sealing and imaging condition (blue curve) is modeled with a 45 s time lapse between seal and image.

Number of enzymes per well	Substrate turnover rate (s ⁻¹)			
	1	6	10	50
time (s)				
1	187	1121	1868	9338
30	186	1109	1834	8508
60	186	1096	1800	7666
90	186	1084	1766	6850
120	185	1071	1731	6072
150	185	1059	1697	5338
% activity remaining	99.1%	94.5%	90.9%	57.2%

Supporting Table 1. Data showing the effect of substrate depletion on substrate turnover over time as the number of enzymes per well is varied. At 1 enzyme per well, the amount of substrate converted to product is small resulting in negligible substrate depletion. The result is nearly constant substrate turnover. At higher levels of enzymes per well, the effect of substrate depletion is more dramatic, resulting in reduced substrate turnover with time.

(1) Details of the Chromalink reagent are provided at the Solulink website (<http://store.solulink.com/collections/biotin-labeling>)

(2) Hermanson, G. T. *Bioconjugate Techniques*; Academic Press: San Diego, 1996.

(3) Rissin, D. M.; Gorris, H. H.; Walt, D. R. *J. Am. Chem. Soc.* **2008**, *130*, 5349-5353.

(4) English, B. P.; Min, W.; van Oijen, A. M.; Lee, K. T.; Luo, G.; Sun, H.; Cherayil, B. J.; Kou, S. C.; Xie, X. S. *Nat Chem Biol* **2006**, *2*, 87-94.